drugset / Trial / NCT02696642
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment
Timeline
- Start
- 2016-04-14
- Primary completion
- 2018-07-31
- Completion
- 2019-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anetumab Ravtansine | Monoclonal antibody | 6.5 mg/kg | Intravenous |